Search - tctmd.com

Displaying 461 - 480 of 513

Sort: Relevancy | Date

News Daily News

High Platelet Reactivity Linked to More Adverse Events After Endovascular Procedures

Yael L. Maxwell

April 26, 2013

News Conference News ACC 2013

Aspirin Alone Just as Good as Dual Antiplatelet Therapy Beyond 12 Months

Jason Kahn

March 11, 2013

News Conference News ACC 2013

Cangrelor Consistently Comes Out Ahead of Clopidogrel in All PCI Patients

Yael L. Maxwell

March 09, 2013

Presentation TCT 2013

Impact of Anti-anginal Therapy and Rate Pressure Product Control on the Need for Repeat Revascularization Post-PCI

Presenter: Subhash Banerjee, Rick Weideman, Bertis Little, Mark Weideman, Jennifer Gunter, Kevin Kelly, Emmanouil Brilakis

January 31, 2013

News Daily News

PLATO Substudy: Ticagrelor Advantage Persists After First Ischemic Event

January 07, 2013

News Daily News

Una Dosis Alta de Aspirina tras una PCI Primaria aumenta las Hemorragias No observandose Beneficio Isquémico alguno

L.A. McKeown

December 19, 2012

News Daily News

High-Dose Aspirin After Primary PCI Increases Bleeding with No Ischemic Benefit

L.A. McKeown

December 19, 2012

News Daily News

Clopidogrel Pretreatment Reduces Cardiac Events, Not Mortality, After PCI

Yael L. Maxwell

December 19, 2012

News Daily News

Risk Factor Control Linked to Better Outcomes After Peripheral Intervention

Caitlin E. Cox

December 16, 2012

News Daily News

El Control del Factor de Riesgo se asocia a Mejores Resultados tras una Intervención Periférica

Caitlin E. Cox

December 16, 2012

News Daily News

Extended Dual Antiplatelet Therapy Lowers Death, MI Rates in DES Patients

Jason Kahn

December 05, 2012

Presentation ESC 2012

Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial

Presenter: Matthew Roe

August 28, 2012

News Conference News ESC 2012

Prolonged Vorapaxar Enhances Secondary Prevention in Selected Post-MI Patients

August 26, 2012

News Conference News ESC 2012

Comparable Long-Term Safety, Efficacy with Prasugrel, Clopidogrel in ACS

August 26, 2012

News Daily News

Pantoprazole Not Necessarily a Safer PPI Choice for Patients on Dual Antiplatelet Therapy

L.A. McKeown

August 01, 2012

News Daily News

Guidelines Elevate Ticagrelor to First-line Antiplatelet Status in Unstable Angina

Jason Kahn

July 17, 2012

Presentation

Cilostazol Added to Aspirin and Clopidogrel Reduces Revascularization Without Increases in Major Adverse Events in Patients With DES

Presenter: Ryota Sakurai

July 12, 2012

News Daily News

HORIZONS-AMI: Similar Outcomes with Abciximab, Eptifibatide During Primary PCI

July 05, 2012

News Daily News

CHARISMA Genetics Analysis: CYP2C19 Variants Show Little Clinical Impact

April 10, 2012

News Conference News ACC 2012

Three Months of Antiplatelet Therapy with Endeavor Equal to 1 Year with Other DES

Jason Kahn

March 24, 2012

Advertisement

High Platelet Reactivity Linked to More Adverse Events After Endovascular Procedures

Aspirin Alone Just as Good as Dual Antiplatelet Therapy Beyond 12 Months

Cangrelor Consistently Comes Out Ahead of Clopidogrel in All PCI Patients

Impact of Anti-anginal Therapy and Rate Pressure Product Control on the Need for Repeat Revascularization Post-PCI

PLATO Substudy: Ticagrelor Advantage Persists After First Ischemic Event

Una Dosis Alta de Aspirina tras una PCI Primaria aumenta las Hemorragias No observandose Beneficio Isquémico alguno

High-Dose Aspirin After Primary PCI Increases Bleeding with No Ischemic Benefit

Clopidogrel Pretreatment Reduces Cardiac Events, Not Mortality, After PCI

Risk Factor Control Linked to Better Outcomes After Peripheral Intervention

El Control del Factor de Riesgo se asocia a Mejores Resultados tras una Intervención Periférica

Extended Dual Antiplatelet Therapy Lowers Death, MI Rates in DES Patients

Prasugrel vs. Clopidogrel for Acute Coronary Syndromes Patients Managed without Revascularization — the TRILOGY ACS trial

Prolonged Vorapaxar Enhances Secondary Prevention in Selected Post-MI Patients

Comparable Long-Term Safety, Efficacy with Prasugrel, Clopidogrel in ACS

Pantoprazole Not Necessarily a Safer PPI Choice for Patients on Dual Antiplatelet Therapy

Guidelines Elevate Ticagrelor to First-line Antiplatelet Status in Unstable Angina

Cilostazol Added to Aspirin and Clopidogrel Reduces Revascularization Without Increases in Major Adverse Events in Patients With DES

HORIZONS-AMI: Similar Outcomes with Abciximab, Eptifibatide During Primary PCI

CHARISMA Genetics Analysis: CYP2C19 Variants Show Little Clinical Impact

Three Months of Antiplatelet Therapy with Endeavor Equal to 1 Year with Other DES

Advertisement

Advertisement

Sign In

Forgot Your Password?

Search TCTMD

CME TITLE

Sign up for our newsletter

Search TCTMD

Submit an Event

Become a PREMIUM MEMBER or LOG IN to view exclusive content

REGISTER for free or LOG IN to view this content